AR080065A1 - Proceso para preparar moduladores del regulador de conductancia transmembrana de fibrosis quistica - Google Patents
Proceso para preparar moduladores del regulador de conductancia transmembrana de fibrosis quisticaInfo
- Publication number
- AR080065A1 AR080065A1 ARP100103914A ARP100103914A AR080065A1 AR 080065 A1 AR080065 A1 AR 080065A1 AR P100103914 A ARP100103914 A AR P100103914A AR P100103914 A ARP100103914 A AR P100103914A AR 080065 A1 AR080065 A1 AR 080065A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- fibrosis transmembrane
- conductance regulator
- transmembrane conductance
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Incluye el Compuesto 1 Forma A, Compuesto 1 Forma A-HCl, Compuesto 1 Forma B y Compuesto 1 Forma B-HCl, cualquier combinacion de estas formas, composiciones farmacéuticas que las comprenden y métodos de tratamiento que las emplean. Reivindicacion 1: Un proceso para elaborar una forma sustancialmente cristalina del compuesto (1): que comprende: (a) hacer reaccionar el Compuesto (2) con el Compuesto (3) en presencia de un agente de acoplamiento, en donde el agente de acoplamiento se selecciona del grupo que consiste en tetrafluoroborato de 2-cloro-1,3-dimetil-2-imidazolio, HBTU, HCTU, 2-cloro-4,6-dimetoxi-1,3,5-triazina, HATU, HOBT/EDC y T3P«.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25463409P | 2009-10-23 | 2009-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080065A1 true AR080065A1 (es) | 2012-03-14 |
Family
ID=43530872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103914A AR080065A1 (es) | 2009-10-23 | 2010-10-25 | Proceso para preparar moduladores del regulador de conductancia transmembrana de fibrosis quistica |
Country Status (16)
Country | Link |
---|---|
US (4) | US8344147B2 (es) |
EP (1) | EP2491018A1 (es) |
JP (1) | JP5789611B2 (es) |
KR (1) | KR20120104554A (es) |
CN (1) | CN102648182A (es) |
AR (1) | AR080065A1 (es) |
AU (1) | AU2010310612A1 (es) |
BR (1) | BR112012009583A2 (es) |
CA (1) | CA2778492A1 (es) |
IL (1) | IL219326A0 (es) |
MX (1) | MX2012004790A (es) |
NZ (1) | NZ600172A (es) |
RU (1) | RU2553989C2 (es) |
TW (1) | TWI475023B (es) |
WO (1) | WO2011050215A1 (es) |
ZA (1) | ZA201202915B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
KR20060088537A (ko) | 2003-09-06 | 2006-08-04 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절자 |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
PL1773816T3 (pl) | 2004-06-24 | 2015-06-30 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
NZ566208A (en) | 2005-08-11 | 2010-09-30 | Vertex Pharma | 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators |
EP3208272B1 (en) | 2005-11-08 | 2020-01-08 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
EP2016065B1 (en) | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
PL3327016T3 (pl) | 2006-04-07 | 2021-10-04 | Vertex Pharmaceuticals Incorporated | Wytwarzanie modulatorów transporterów posiadających kasetę wiążącą ATP |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
HUE028426T2 (en) | 2007-08-24 | 2016-12-28 | Vertex Pharma | Isothiazolopyridinones for (inter alia) treating cystic fibrosis |
EP3012250B1 (en) | 2007-11-16 | 2017-11-08 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
RS55559B1 (sr) | 2007-12-07 | 2017-05-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline |
AU2008335439A1 (en) * | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
EA201070700A1 (ru) * | 2007-12-07 | 2011-06-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения циклоалкилкарбоксамидопиридинбензойных кислот |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
MX2011003249A (es) * | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
BRPI0919930A2 (pt) * | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
MX2011004374A (es) * | 2008-10-23 | 2011-05-23 | Vertex Pharma | Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida. |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
AU2010295461B2 (en) * | 2009-09-17 | 2016-03-03 | Vertex Pharmaceuticals Incorporated | Process for preparing azabicyclic compounds |
RU2568608C2 (ru) * | 2009-10-23 | 2015-11-20 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
KR101984225B1 (ko) | 2010-04-22 | 2019-05-30 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
AR081920A1 (es) * | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
ME02650B (me) | 2011-11-08 | 2017-06-20 | Vertex Pharma | Modulatori atp- vezujućih kasetnih transportera |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftr媒介性疾患の処置のための医薬組成物を調製する方法 |
PT3925607T (pt) | 2014-04-15 | 2023-09-26 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
JP7158717B2 (ja) * | 2017-11-22 | 2022-10-24 | 国立大学法人九州工業大学 | 求電子的アジド化剤又はジアゾ化剤 |
CN109369798B (zh) * | 2018-12-25 | 2020-09-15 | 苏州天马医药集团天吉生物制药有限公司 | 一种合成索玛鲁肽的方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
AU735186B2 (en) * | 1997-09-15 | 2001-07-05 | Warner Chilcott Company, Llc | Antimicrobial quinolones, their compositions and uses |
ATE303993T1 (de) * | 1997-12-22 | 2005-09-15 | Pharmacia & Upjohn Co Llc | 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe |
PL1773816T3 (pl) * | 2004-06-24 | 2015-06-30 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
CN101821266B (zh) * | 2007-09-14 | 2014-03-12 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
CN101939054B (zh) | 2007-12-10 | 2014-10-29 | 诺华股份有限公司 | 有机化合物 |
BRPI0919930A2 (pt) * | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
MX2011004374A (es) * | 2008-10-23 | 2011-05-23 | Vertex Pharma | Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida. |
RU2568608C2 (ru) * | 2009-10-23 | 2015-11-20 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида |
-
2010
- 2010-10-21 WO PCT/US2010/053628 patent/WO2011050215A1/en active Application Filing
- 2010-10-21 CN CN2010800533805A patent/CN102648182A/zh active Pending
- 2010-10-21 KR KR1020127013136A patent/KR20120104554A/ko not_active Application Discontinuation
- 2010-10-21 EP EP10775986A patent/EP2491018A1/en not_active Withdrawn
- 2010-10-21 MX MX2012004790A patent/MX2012004790A/es active IP Right Grant
- 2010-10-21 US US12/909,750 patent/US8344147B2/en active Active
- 2010-10-21 RU RU2012121160/04A patent/RU2553989C2/ru not_active IP Right Cessation
- 2010-10-21 AU AU2010310612A patent/AU2010310612A1/en not_active Abandoned
- 2010-10-21 JP JP2012535392A patent/JP5789611B2/ja not_active Expired - Fee Related
- 2010-10-21 BR BR112012009583A patent/BR112012009583A2/pt not_active IP Right Cessation
- 2010-10-21 NZ NZ600172A patent/NZ600172A/en not_active IP Right Cessation
- 2010-10-21 CA CA2778492A patent/CA2778492A1/en not_active Abandoned
- 2010-10-22 TW TW099136180A patent/TWI475023B/zh not_active IP Right Cessation
- 2010-10-25 AR ARP100103914A patent/AR080065A1/es unknown
-
2012
- 2012-04-20 ZA ZA2012/02915A patent/ZA201202915B/en unknown
- 2012-04-22 IL IL219326A patent/IL219326A0/en unknown
- 2012-11-16 US US13/678,840 patent/US8754222B2/en active Active
-
2014
- 2014-03-07 US US14/200,656 patent/US8884018B2/en active Active
- 2014-07-09 US US14/326,930 patent/US20140336393A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL219326A0 (en) | 2012-06-28 |
US8754222B2 (en) | 2014-06-17 |
US8884018B2 (en) | 2014-11-11 |
NZ600172A (en) | 2014-07-25 |
RU2553989C2 (ru) | 2015-06-20 |
AU2010310612A2 (en) | 2012-08-16 |
EP2491018A1 (en) | 2012-08-29 |
US20140336393A1 (en) | 2014-11-13 |
AU2010310612A1 (en) | 2012-06-14 |
CN102648182A (zh) | 2012-08-22 |
JP5789611B2 (ja) | 2015-10-07 |
US20110124869A1 (en) | 2011-05-26 |
US20140187787A1 (en) | 2014-07-03 |
KR20120104554A (ko) | 2012-09-21 |
WO2011050215A1 (en) | 2011-04-28 |
US20130072687A1 (en) | 2013-03-21 |
TW201120044A (en) | 2011-06-16 |
ZA201202915B (en) | 2013-06-26 |
RU2012121160A (ru) | 2013-11-27 |
US8344147B2 (en) | 2013-01-01 |
JP2013508406A (ja) | 2013-03-07 |
BR112012009583A2 (pt) | 2015-09-29 |
MX2012004790A (es) | 2013-02-01 |
CA2778492A1 (en) | 2011-04-28 |
TWI475023B (zh) | 2015-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080065A1 (es) | Proceso para preparar moduladores del regulador de conductancia transmembrana de fibrosis quistica | |
PE20181295A1 (es) | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala | |
CY1119426T1 (el) | Απορρυπαντικο ρουχων | |
CY1115254T1 (el) | Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις | |
UY36075A (es) | Derivados de tubulisina | |
UY33017A (es) | Tratamiento para trastornos gastrointestinales | |
MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
CL2008002394A1 (es) | Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos. | |
JOP20200024A1 (ar) | مركبات ثنائي هيدروكساديازينون | |
UY37250A (es) | Derivados macrocíclicos de indol | |
CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
ECSP11011021A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
PT3397291T (pt) | Difusor de agentes activos, tal como insecticidas, perfumes, detergentes ou desinfectantes, e seu processo de fabrico | |
GT201600232A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
BR112018007110A2 (pt) | processo de preparação para uma unidade de fornecimento de água de serviço | |
MX2018006226A (es) | Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. | |
CL2007002206A1 (es) | Procedimiento; y aparato para tratar, sanitizar o esterilizar un contenedor de alimentos que comprende proveer una solucion de clo2, extraer el dioxido desde la solucion e inyectarlo al contenedor; procedimiento; y aparato para separar clo2 de una solucion; y procedimiento para preparar una solucion de clo2. | |
AR099558A1 (es) | Régimen de dosaje del compuesto fgf-18 | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
MX2011011618A (es) | Agentes terapeuticos 713. | |
UY35307A (es) | Composición antifúngica tópica para el tratamiento de onicomicosis | |
MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. | |
UY32447A (es) | Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |